Industry Growth Insights published a new data on “CAR-T Therapy in Haematological Malignancy Market”. The research report is titled “CAR-T Therapy in Haematological Malignancy Market research by Types (Allogeneic, Autologous), By Applications (Hospitals, Cancer Research Centers, Others), By Players/Companies Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics, Mustang Bio, Bluebird Bio, Collectis, Allogene Therapeutics, Celyad”.
Scope Of The Report
Report Attributes
Report Details
Report Title
CAR-T Therapy in Haematological Malignancy Market Research Report
By Type
Allogeneic, Autologous
By Application
Hospitals, Cancer Research Centers, Others
By Companies
Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics, Mustang Bio, Bluebird Bio, Collectis, Allogene Therapeutics, Celyad
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
139
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global CAR-T Therapy in Haematological Malignancy Market Report Segments:
The global CAR-T Therapy in Haematological Malignancy market is segmented on the basis of:
Types
Allogeneic, Autologous
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Cancer Research Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene (Juno Therapeutics)
- Novartis
- Gilead (Kite Pharma)
- Pfizer
- CARsgen Therapeutics
- Autolus Therapeutics
- Aurora BioPharma
- Sorrento Therapeutics
- Mustang Bio
- Bluebird Bio
- Collectis
- Allogene Therapeutics
- Celyad
Highlights of The CAR-T Therapy in Haematological Malignancy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Allogeneic
- Autologous
- By Application:
- Hospitals
- Cancer Research Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CAR-T Therapy in Haematological Malignancy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CAR-T therapy is a new type of cancer treatment that uses genetically modified T cells to fight cancer. CAR-T therapy works by helping the T cells recognize and attack specific tumors.
Some of the major companies in the car-t therapy in haematological malignancy market are Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics, Mustang Bio, Bluebird Bio, Collectis, Allogene Therapeutics, Celyad.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CAR-T Therapy in Haematological Malignancy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CAR-T Therapy in Haematological Malignancy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CAR-T Therapy in Haematological Malignancy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CAR-T Therapy in Haematological Malignancy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CAR-T Therapy in Haematological Malignancy Market Size & Forecast, 2018-2028
4.5.1 CAR-T Therapy in Haematological Malignancy Market Size and Y-o-Y Growth
4.5.2 CAR-T Therapy in Haematological Malignancy Market Absolute $ Opportunity
Chapter 5 Global CAR-T Therapy in Haematological Malignancy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type
5.2.1 Allogeneic
5.2.2 Autologous
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global CAR-T Therapy in Haematological Malignancy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 CAR-T Therapy in Haematological Malignancy Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Cancer Research Centers
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CAR-T Therapy in Haematological Malignancy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CAR-T Therapy in Haematological Malignancy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America CAR-T Therapy in Haematological Malignancy Analysis and Forecast
9.1 Introduction
9.2 North America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type
9.6.1 Allogeneic
9.6.2 Autologous
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Cancer Research Centers
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe CAR-T Therapy in Haematological Malignancy Analysis and Forecast
10.1 Introduction
10.2 Europe CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type
10.6.1 Allogeneic
10.6.2 Autologous
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe CAR-T Therapy in Haematological Malignancy Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Cancer Research Centers
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific CAR-T Therapy in Haematological Malignancy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type
11.6.1 Allogeneic
11.6.2 Autologous
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific CAR-T Therapy in Haematological Malignancy Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Cancer Research Centers
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America CAR-T Therapy in Haematological Malignancy Analysis and Forecast
12.1 Introduction
12.2 Latin America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type
12.6.1 Allogeneic
12.6.2 Autologous
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Cancer Research Centers
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) CAR-T Therapy in Haematological Malignancy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type
13.6.1 Allogeneic
13.6.2 Autologous
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) CAR-T Therapy in Haematological Malignancy Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Cancer Research Centers
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CAR-T Therapy in Haematological Malignancy Market: Competitive Dashboard
14.2 Global CAR-T Therapy in Haematological Malignancy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celgene (Juno Therapeutics)
14.3.2 Novartis
14.3.3 Gilead (Kite Pharma)
14.3.4 Pfizer
14.3.5 CARsgen Therapeutics
14.3.6 Autolus Therapeutics
14.3.7 Aurora BioPharma
14.3.8 Sorrento Therapeutics
14.3.9 Mustang Bio
14.3.10 Bluebird Bio
14.3.11 Collectis
14.3.12 Allogene Therapeutics
14.3.13 Celyad
